BioCentury
ARTICLE | Clinical News

Five Prime reports Phase I data for cabiralizumab in pancreatic cancer

November 17, 2017 4:59 AM UTC

Five Prime Therapeutics Inc. (NASDAQ:FPRX) reported preliminary data from a Phase I trial of cabiralizumab (FPA008) in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid tumors and announced upcoming trials sponsored by partner Bristol-Myers Squibb Co. (NYSE:BMY).

Among 31 evaluable pancreatic cancer patients in the trial, cabiralizumab plus Opdivo led to an objective response rate (ORR) of 13%, including 4 partial responses in heavily pretreated patients without microsatellite instability (MSI), and a durable clinical benefit rate (CBR) of 16%. Five Prime said that historically, pancreatic cancer without MSI does not respond to monotherapy with drugs that inhibit PD-1...